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BACKGROUND: Fragile X syndrome (FXS) is a neurodevelopmental disorder caused by epigenetic silencing of FMR1
and loss of FMRP expression. Efforts to understand the molecular underpinnings of the disease have been largely
performed in rodent or nonisogenic settings. A detailed examination of the impact of FMRP loss on cellular processes
and neuronal properties in the context of isogenic human neurons remains lacking.
METHODS: Using CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9 to introduce indels in
exon 3 of FMR1, we generated an isogenic human pluripotent stem cell model of FXS that shows complete loss of
FMRP expression. We generated neuronal cultures and performed genome-wide transcriptome and proteome
profiling followed by functional validation of key dysregulated processes. We further analyzed neurodevelopmental
and neuronal properties, including neurite length and neuronal activity, using multielectrode arrays and patch
clamp electrophysiology.
RESULTS: We showed that the transcriptome and proteome profiles of isogenic FMRP-deficient neurons
demonstrate perturbations in synaptic transmission, neuron differentiation, cell proliferation and ion
transmembrane transporter activity pathways, and autism spectrum disorder–associated gene sets. We uncovered
key deficits in FMRP-deficient cells demonstrating abnormal neural rosette formation and neural progenitor cell
proliferation. We further showed that FMRP-deficient neurons exhibit a number of additional phenotypic
abnormalities, including neurite outgrowth and branching deficits and impaired electrophysiological network
activity. These FMRP-deficient related impairments have also been validated in additional FXS patient–derived
human-induced pluripotent stem cell neural cells.
CONCLUSIONS: Using isogenic human pluripotent stem cells as a model to investigate the pathophysiology of FXS
in human neurons, we reveal key neural abnormalities arising from the loss of FMRP.
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https://doi.org/10.1016/j.biopsych.2020.05.005Fragile X syndrome (FXS) is the most common genetic cause
of intellectual disability (1). In addition to cognitive impairment,
individuals with FXS often exhibit seizures, hypersensitivity,
impulsivity, and social anxiety (2). FXS is caused by a CGG
repeat expansion in the 5ʹ untranslated region of the FMR1
gene, which results in silencing of FMR1 and loss of FMRP, its
encoded protein (3). FMRP, a brain-enriched RNA binding
protein, has been shown to regulate the translation of more
than 800 messenger RNAs in neurons (4). Loss of translational
regulation of these messenger RNAs, whose products are
involved in a wide range of neurodevelopmental processes, is
thought to underlie the pleiotropic molecular and clinical
manifestations of FXS (5). Despite continued therapeutic ef-
forts, effective treatments are yet to be developed (6).N: 0006-3223Fmr1 knockout (KO) animals have been the predominant
system used to model FXS (7). Fmr1 KO mice exhibit a
number of phenotypes reminiscent of symptoms seen in in-
dividuals with FXS such as increased susceptibility to sei-
zures and sensory hypersensitivity, hyperactivity,
perseveration, and repetitive behaviors (7). A number of
molecular and synaptic defects have also been identified in
FXS rodent models (8), including abnormal dendritic spine
morphology (9), protein synthesis (10), and neurotransmis-
sion (11), paving the way for the discovery and interrogation
of possible therapeutic targets (6).
Human pluripotent stem cells (hPSCs) have emerged
during recent years as a powerful tool to investigate the
pathogenesis of neurological diseases in the context ofª 2020 Society of Biological Psychiatry. 1
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neurons have begun to reveal cellular defects, including
abnormal morphologies and aberrant synaptic function
(13–19). However, with few exceptions (20–22), a caveat of
the majority of the FXS hPSC studies published to date is the
use of disease and control hPSC lines with different genetic
backgrounds. Here, we generated an isogenic FMR1 KO
(FMR1KO) human embryonic stem cell (hESC) model, per-
formed integrative transcriptome and proteome analyses of
FMRP-deficient neurons, and describe their use toward
investigating the pathophysiology of FXS in the context of
human neural cells.
METHODS AND MATERIALS
Cell Culture and Neural Differentiation
The cell lines used in this study were HEK293T cells, control
H1/WA01 (23) and WCMC-37 FXS (24) hESCs, and four pre-
viously described control and FXS human-induced pluripotent
stem cells (hiPSCs) (25). The isogenic FMR1KO hESC lines
were generated by CRISPR (clustered regularly interspaced
short palindromic repeats)/Cas9 editing the H1 line. Subse-
quent differentiations into neural progenitor cells (NPCs) (26)
and neurons (27) were carried out as described in the
Supplemental Methods in Supplement 1.
Protein Assays
Immunofluorescence and immunoblot were carried out as
described previously (28). Full details, including all antibodies
used, can be found in the Supplemental Methods in
Supplement 1.
Neuronal Phenotyping Assays
For neurite outgrowth measurement, NPCs were plated at a
low density and placed into an IncuCyte ZOOM imaging sys-
tem (Essen Bioscience, Ann Arbor, MI) for recording. For
microelectrode array (MEA) measurement, day 37 neurons
were plated on 0.1% polyethylenimine-coated MEA plates
(Axion Biosystems, Atlanta, GA) in BrainPhys media (StemCell
Technologies, Vancouver, British Columbia, Canada). Spon-
taneous field potential activity was recorded at 37oC for 5
minutes every 2 or 3 days using the Maestro MEA system
(Axion Biosystems). For patch clamp, electrophysiological re-
cordings were conducted on neurons cultured on glass cov-
erslips and transferred to a recording chamber. Full details of
the neurite growth assay, MEA, and patch clamp recordings
can be found in the Supplemental Methods in Supplement 1.
Omics Profiling
Cells were harvested on day 37 of neuronal differentiation. For
RNA sequencing (RNA-seq), paired-end 150-base-pair
sequencing and 20 million reads per sample using a HiSeq
4000 system were performed by Novogene (Hong Kong). For
proteomic mass spectrometry (MS) analysis, samples were
prepared as described previously (29,30) with optimization for
pellet cells. Full details of the RNA-seq and proteomics sample
preparation, workflow, and data analysis can be found in the
Supplemental Methods in Supplement 1.2 Biological Psychiatry - -, 2020; -:-–- www.sobp.org/journalThe RNA-seq and MS-based proteomics data have been
deposited in the GEO (Gene Expression Omnibus) and Pro-
teomeXchange consortium under the identifiers GSE117248
and PXD011630, respectively.
Neural Progenitor Assays
For neural rosette (NR) formation assay, hESCs/hiPSCs were
dissociated with Accutase and seeded into AggreWell 800
plates (StemCell Technologies) to form neural aggregates in
StemDiff Neural Induction Medium (StemCell Technologies).
On day 5 neural aggregates were transferred into poly-L-
ornithine/laminin-coated plates, and on day 10 they were
fixed with 4% paraformaldehyde/phosphate-buffered saline.
For cell proliferation assay, approximately 70% confluent
NPCs were treated with 50 mM BrdU for 6 hours and fixed with
4% formaldehyde. Full details can be found in the
Supplemental Methods in Supplement 1.RESULTS
Generation of Isogenic FMR1KO hESCs
Isogenic hPSCs are important tools to model genetic disorders
in the context of a common genetic background while working
in cell types of interest. To generate FMR1KO hESCs, we used
CRISPR/Cas9 targeting exon 3 of FMR1 in the male H1 hESC
line (Figure S1A in Supplement 1). We evaluated the on-target
activity of the FMR1-targeting single guide RNAs in HEK293
cells using the Surveyor assay and confirmed cleavage for
both single guide RNAs (Figure S1B in Supplement 1).
Following electroporation of plasmids into the control hESCs,
clones were screened for indels in FMR1 (Figure S1C in
Supplement 1). In total, 8 clones (out of w48 screened) with
indels in FMR1 were obtained, of which 2 clones with 8 and 17
base pair deletions (termed FMR1KO1 and FMR1KO2,
respectively) were selected for further characterization
(Figure S1A, D in Supplement 1). Polymerase chain reaction
amplification for Cas9 in both FMR1KO lines confirmed no
integration of the Cas9 transgene in the targeted clones
(Figure S1E in Supplement 1).
To characterize the FMR1KO lines, we included a previously
described FXS hESC line (24) in our assessments. The plu-
ripotency of the isogenic FMR1KO hESCs was not affected by
the targeting process, as indicated by the uniform expression
of pluripotency markers (Figure S1F in Supplement 1). We also
confirmed that the isogenic hESC lines can differentiate into
cells of the 3 germ layers (Figure S1G in Supplement 1) and do
maintain a normal karyotype (Figure S1H in Supplement 1).
We next analyzed expression levels of FMRP. Although
FMR1 transcripts were detected in the FMR1KO clones
(Figure S2A in Supplement 1), we observed no expression of
FMRP in FMR1KO hESCs by immunoblotting and immuno-
fluorescence imaging (Figure 1B and Figures S1F and S2B in
Supplement 1), consistent with FXS hESCs. Furthermore,
proteome MS analysis confirmed the absence of FMRP pep-
tides in the FXS and FMR1KO lines (Figure S2C in Supplement
1). While some studies have shown that expression of FMRP
may be maintained in FXS hESCs (24,31,32), our results are
Figure 1. Generation of FMR1KO hESCs using CRISPR-Cas9 system. (A) Confirmation of indel and purity by Sanger sequencing. The schematic diagram
shows the position of sgRNA sequence and indels generated in FMR1KO#1 and FMR1KO#2. (B) Immunoblot analysis showing absence of FMRP expression
in FXS, FMR1KO#1, and FMR1KO#2. FMRP (80 kDa) and calnexin (67 kDa) are shown. (C) Schematic of neuronal differentiation workflow. (D) Flow cytometry
analysis of cellular composition following hPSC neuronal differentiation using cell surface markers of neurons and glia. (E) Immunofluorescence staining of
MAP2/TUJ1-positive GABAergic (GABA1) and glutamatergic (TBR11) neurons differentiated from control, FXS, and FMR1KO1 hESC lines. (F) Quantification
of GABAergic and glutamatergic neurons based on anti-GABA and anti-TBR1 immunostaining. cAMP, cyclic adenosine monophosphate; CRISPR, clustered
regularly interspaced short palindromic repeats; FMR1KO, FMR1 knockout; FXS, fragile X syndrome; GABA, gamma-aminobutyric acid; H1, control; hESC,
human embryonic stem cell; hPSC, human pluripotent stem cell; MEA, microelectrode array; NPC, neural progenitor cell; RNA-Seq, RNA sequencing; sgRNA,
single guide RNA.
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FXS hESCs (33).
Transcriptome and Proteome Analyses Reveal
Cellular Pathways Altered in FMRP-Deficient
Neurons
To further investigate neural deficits caused by loss of FMRP,
we differentiated control, FMR1KO1, and FXS hESCs intoB
neurons using a previously described protocol (26)
(Figure 1C). Flow cytometry analysis showed that the pro-
portions of neural and glial cells derived from the different
lines were comparable (Figure 1D). Characterization of the
neuronal populations showed them to be composed mostly
of glutamatergic TBR11 neurons (w65%–80%) with a lower
proportion of GABAergic (gamma-aminobutyric acidergic)
neurons (w20%) (Figure 1E, F).iological Psychiatry - -, 2020; -:-–- www.sobp.org/journal 3
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of FMRP, we performed RNA-seq on day 37 control (H1),
FMR1KO1, and FXS neurons (n = 4/genotype). Principal
component analysis of the transcriptional profiles showed tight
clustering of biological replicates per genotype (Figure 2A). We
identified a substantially higher number of differentially
expressed genes (DEGs) in FMR1KO neurons versus isogenic
control neurons compared with FXS neurons versus control
neurons, as depicted in the volcano plots (Figure 2B, C). In
total, we identified an overlap of 3110 DEGs from FXS and
FMR1KO neurons that were altered compared with control
neurons, of which 1525 genes were downregulated and 1585
were upregulated (Figure 2D–G). Further statistical analysis
with a threshold of log2 fold change (FC) reduced the number
of DEGs substantially, indicating that most of the DEGs (83%–
97%) had smaller fold changes (jlog2FCj . 0). Separation of
the DEGs by log2FC showed that 17%, 7%, and 3% of the
DEGs had a jlog2FCj . 1, . 1.5, and . 2, respectively
(Figure 2F). Clustering of the 3110 DEGs showed high corre-
lation between expression levels in FXS and FMR1KO sam-
ples, supporting the current selection of genes of interest
(Figure 2G). Functional annotation of DEGs shared between
FMR1KO and FXS using Gene Ontology (GO) analysis and
network visualization showed enrichment of a number of GO
terms, including those related to neuron differentiation and
neurodevelopment, neurogenesis, and neurotransmission for
downregulated genes and RNA processing and transport,
translation, and cell cycle processes for upregulated genes
(Figure 2H, Figure S3A in Supplement 1, and Table S3 in
Supplement 2). Among the neuronal differentiation GO cate-
gories, we identified genes involved in axon guidance, neurite
outgrowth, and cell adhesion such as DSCAM, GAP43, and
PTPRT. We validated the changes detected by RNA-seq using
quantitative real-time polymerase chain reaction (Figure S3B in
Supplement 1).
We compared our DEGs list with two published tran-
scriptome datasets of FXS neurons (16,34), where we found a
solid overlap of the identified genes (Figure S4A in Supplement
1). From the shared genes among the 3 studies, we found that
approximately 50% of our significant DEGs were shared with
either the Boland et al. (34) or Halevy et al. (16) study
(Figure S4B and Table S7 in Supplement 1). Importantly, we
found a significant association between our DEGs and 239
SFARI genes, an autism-related genes database (35)
(Figure S4C, D and Table S7 in Supplement 1) (jlog2FCj . 0,
p = 6.35 3 10210 and jlog2FCj . 1, p = 7.82 3 1023). We also
observed significant association for DEGs with jlog2FCj. 0 for
FMRP substrates (246 genes, p = 1.13 10229) (Figure S4C and
Table S7 in Supplement 1). Together, our findings support that=
Figure 2. Global transcriptional changes in FMRP-deficient neurons. (A) PCA sh
of 2log10 (p value) versus the log2 (fold change) of transcript levels for all genes.
upregulated genes are shown in red. (D, E) Venn diagram analysis showing genes
FXS and control vs. FMR1KO. (F) Bar plot showing the number of significant ch
entially expressed genes that are common to FXS and FMR1KO neurons. (H) Fu
neurons. (Functional annotation of common upregulated genes can be found in
significance, and the GO terms are grouped and linked based on the similarity of t
group shown in bold. (A full list of enriched network biological processes with co
FMR1 knockout; FXS, fragile X syndrome; GO, Gene Ontology; PCA, principal c
B
loss of FMRP results in transcriptional dysregulation, which
alters processes involved in central nervous system develop-
ment such as neuronal differentiation, neurogenesis, and cell
cycle regulation.
We collected day 37 neurons, the same time point used for
the transcriptome analysis, and subsequently profiled the
proteome by MS analysis. As a quality control, we compared
protein and peptide numbers and evaluated the reproducibility,
in which we identified a total of 5007 proteins, where 4210
were selected for further investigation after stringent filtering,
and compared protein and peptide identification across the 3
genotypes (Figure S5A, B in Supplement 1). The majority of
selected proteins were shared among all 3 genotypes
(Figure S5C in Supplement 1). Furthermore, we observed
strong reproducibility (Pearson correlations = .97–.98) between
biological replicates (Figure S5D in Supplement 1), which was
further supported by principal component analysis demon-
strating strong separation of the 3 genotypes (Figure 3A). Next,
we performed a system-wide comparison in more detail
comparing FXS and FMR1KO with control (Figure 3B,C and
Figure S5E, F in Supplement 1). Similar to transcriptome sta-
tistical analysis, the vast majority of significantly differentially
expressed (DE) proteins depict smaller log2FCs (jlog2FCj . 0),
with only 17% and 13% of downregulated and upregulated
proteins, respectively, showing log2FCs beyond 1 (jlog2FCj .
1) (Figure S5E in Supplement 1). Hierarchical clustering shows
grouping of the samples according to the expected genotypes,
whereas column values suggest a closer correlation between
FXS and FMR1KO expression levels than with expression
levels in control samples (Figure S5F in Supplement 1). We
identified several protein changes, with a total of 577 and 2198
proteins exhibiting increased or decreased expression in FXS
and FMR1KO compared with control, respectively, as depicted
in the volcano plot (Figure 3B, C and Table S2 in Supplement
2).
Next, we performed pathway enrichment analysis for DE
proteins in FXS samples (343 downregulated and 234 upre-
gulated proteins) and FMR1KO samples (1247 downregulated
and 951 upregulated proteins) separately (Table S4 in
Supplement 2). The enriched GO terms for DE proteins in
FMR1KO showed similar categories as RNA-seq data
(Table S4 in Supplement 2), whereas the GO terms for DE
proteins in FXS showed enrichment in vesicle transport and
synaptic signaling, cell cycle processes, DNA replication,
and DNA metabolic processes (Table S4 in Supplement 2).
Among the downregulated proteins, we found CNTNAP2
(36,37) GPRIN3, KIF5C (38), and CNTN1, which were previ-
ously associated with FXS and other neurodevelopmental
disorders.owing tight clustering of 4 replicates for each genotype. (B, C) Volcano plots
Relative to control, significantly downregulated genes are shown in blue and
that are similarly downregulated (D) and upregulated (E) between control vs.
anges dependent on the cutoff in log2 fold changes. (G) Heatmap of differ-
nctional annotation of common downregulated genes in FXS and FMR1KO
Figure S3 in Supplement 1.) The size of the nodes reflects their statistical
heir associated genes (kappa score $ .35), with the most significant term per
rresponding p values can be found in Table S3 in Supplement 2.) FMR1KO,
omponent analysis.
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Figure 4. FMRP deficiency leads to abnormal
neural rosette formation and increased neural pro-
genitor proliferation. (A) Immunostaining showing
neural rosette structures identified using Nestin and
ZO-1 expression. (B) Quantification of lumen size
area (based on ZO-1-positive staining). Lumen area
was measured by ImageJ software (National Institute
of Mental Health, Bethesda, MD). Values shown are
mean 6 SEM based on n = 4 biological replicates
per genotype; *p , .05 and ***p , .001 compared
with control was determined by one-way ANOVA
with Tukey’s post hoc test. (C, D) BrdU and Ki67
labeling reveals increased proliferation in FXS and
FMR1KO (KO1) neural progenitor cells compared
with control. Values shown are mean 6 SEM based
on blinded counting of 10 images from each of 3
biological replicates per genotype; *p , .05, **p ,
.01, and ***p , .001 compared with control was
determined by one-way ANOVA with Fisher’s LSD
post hoc test. ANOVA, analysis of variance;
FMR1KO, FMR1 knockout; FXS, fragile X syndrome;
H1, control; LSD, least significant difference.
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performed pathway enrichment analysis for DE proteins shared
between FXS and FMR1KO (244 downregulated and 141 upre-
gulated proteins) (Table S4 sheets with keyword “overlap” in
Supplement 2). We visualized the GO terms for biological pro-
cesses as two networks representing upregulated and down-
regulated common protein changes (Figure S6A, B in
Supplement 1). Interestingly, we found cellular processes based
on downregulated proteins related to neurotransmitter secretion,
synaptic transmission, transport, and dendrite development,
whereas we found cellular processes based on upregulated
proteins related to DNA replication and cell cycle processes.
Importantly, the data reveal many GO categories similar to those
identified in the transcriptional enrichment analysis, highlighting=
Figure 3. Global proteomic changes in FMRP-deficient neurons. (A) PCA show
(p value) versus the log2 (fold change) of protein levels for all proteins. Relati
upregulated proteins are shown in red. (D, E) Venn diagram analysis showing c
between the RNA-seq and proteomics data. There were 77 upregulated protein
notations for the significant common changes, where a subset (based on protein w
Reactome) is displayed and the complete enrichment can be found in Table S5
the common significant upregulated (G) and downregulated (H) changes at both t
purple. ATP, adenosine triphosphate; BP, biological process; CC, cellular compo
FMR1 knockout; FXS, fragile X syndrome; GO, Gene Ontology; MF, molecular func
principal component analysis; RNA-seq, RNA sequencing.
B
the complementary of the proteomic and transcriptional
analyses and providing further evidence linking loss of FMRP
to functional perturbations in these pathways, which is
further supported by the enrichment of both SFARI-
and FMR1/FMRP-related proteins (Figure S7A, B in
Supplement 1). In the proteomics dataset, we found signifi-
cant association with 40 SFARI genes and 57 FMRP sub-
strates (jlog2FCj . 0, p = 8.32 3 1023 and p = 2.12 3 1027,
respectively) (Figure S7A, B and Table S7 in Supplement 1),
suggesting that our findings at the RNA level translated to
the protein level providing another layer of functional
insight. Collectively, our findings highlight several biological
processes and pathways altered in FMRP-deficient neurons
of potential relevance to the pathogenesis of FXS.ing clustering of replicates for each genotype. (B, C) Volcano plots of 2log10
ve to control, significantly downregulated proteins are shown in blue and
ommon significant changes shared between FMR1KO and FXS as well as
s/genes (D) and 110 downregulated proteins/genes (E). (F) Functional an-
ith lowest p value per cluster group for GO terms BP, CC, and MF as well as
in Supplement 2. (G, H) STRING protein–protein interactions network for
he RNA and protein levels. Proteins associated with FMR1 are highlighted in
nent; eIF, eukaryotic initiation factor; ER, endoplasmic reticulum; FMR1KO,
tion; MHC, major histocompatibility complex; mRNA, messenger RNA; PCA,
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tween the two datasets (Figure S8A in Supplement 1). First, we
compared the expression correlation between the two data-
sets and found a good correlation between the RNA and
protein expression (R2 = .42, p = 8.6 3 102171, R2 = .44, p =
9.9 3 102190, and R2 = .42, p = 2.9 3 102171 for control,
FMR1KO, and FXS, respectively) (Figure S8B in Supplement 1).
Notably, we found 187 significant common DEGs and DE
proteins at RNA and protein levels, with 77 and 110 being
upregulated and downregulated, respectively (Figure 3D, E).
This overlap between DEGs and DE proteins is more than that
expected by chance (c2 test, p = 4.1 3 102162). The enrich-
ment analysis on the common changes between the two data
types revealed several altered pathways related to neuro-
transmitter transport, synaptic signaling, neuron differentiation,
and brain development for downregulated proteins/genes
(Figure 3F and Table S5 in Supplement 2) as well DNA repli-
cation, mitosis, and cell cycle for upregulated proteins/genes.
These findings clearly encapsulate the commonalities between
the two datasets and demonstrate that the resources we
describe can be used independently or in combination. To
better understand how these genes and proteins might
interact, we looked into protein–protein interaction networks
using the STRING database (https://string-db.org) (Figure 3G, H).
The networks were plotted using the edge_betweenness clus-
tering algorithm to identify highly connected nodes. This method
clusters together proteins that are known to cooperate and have
correlating gene function annotations (39). From this analysis, we
found 7 genes (COMT, MAP1A, GRIP1, PAK3, SNCA, MAPT,
and CNTNAP2) to be closely associated with FMR1/FMRP, most
of which have associations with neurological and neuropsychi-
atric disorders (40–44). These findings were further supported by
a search for curated gene–disease associations in the DisGeNET
database (http://www.disgenet.org). From our 187 common
candidates, 53 downregulated and 28 upregulated genes were
found to be associated with “nervous system diseases” and
“mental disorders” (Table S8 in Supplement 2).
Loss of FMRP Leads to Abnormal NR and Progenitor
Phenotypes
The omics analysis highlighted changes in neuronal develop-
ment and neurogenesis; therefore, we sought to examine NR
formation as a measure of early neurodevelopment in FMR1KO
and FXS lines. We differentiated hESCs into NRs using an
embryoid body method (45). NR lumens appeared markedly
smaller in the FXS line and both clones of FMR1KO compared
with the control line (Figure 4A). To quantify the size differ-
ences, we measured the area stained with ZO-1, a luminal NR
marker, and found it to be significantly reduced in the two
FMR1KO clones and the FXS line compared with control cells=
Figure 5. FMRP-deficient neurons exhibit shorter neurite length and aberrant
mentation. Neurites are labeled in yellow, and neuronal cell bodies are labeled
shown as mean 6 SD from 6 biological replicates. (C–F) Analysis of neuronal ne
spike time stamps indicating neuronal spontaneous activity as measured by ME
frequency. (F) Number of unresponsive channels; *p , .01, **p , .01, and ***p, .0
post hoc test. (G) Analysis of intrinsic electrophysiological neuronal properties by
fragile X syndrome; G, genotype; H1, control; MEA, multielectrode array; T, time
B
(Figure 4B). Functional annotation of the upregulated genes in
FMRP-deficient neurons showed enrichment of transcripts
involved in mitosis and cell cycle–related processes. This
prompted us to investigate whether cell proliferation is affected
in FMRP-deficient cells. Labeling with BrdU and Ki67, two
markers of cell proliferation, showed increased NPC prolifer-
ation in the FXS line and both FMR1KO clones compared with
control cells (Figure 4C, D).
FMRP-Deficient Neurons Exhibit Neurite Outgrowth
and Branching Deficits
Neurite outgrowth is an early neurodevelopmental process
critical to the proper formation of axons and dendrites that has
been shown to be compromised in a number of intellectual
disability and autism disorders, including FXS (15,17,46). To
evaluate this deficit in FMR1KO lines, we performed longitu-
dinal tracking of neurite elongation in hESC-derived neurons
using live-cell imaging. We found a striking reduction in neurite
outgrowth and branching in FMR1KO and FXS neurons over
time compared with control neurons (Figure 5A, B). These re-
sults demonstrate that FMR1KO neurons recapitulate this
FXS-linked morphological deficit.
FMRP-Deficient Neurons Show Abnormal
Electrophysiological Network Connectivity
We further evaluated extracellular spontaneous activity using
longitudinal MEA recordings, which enable detection of action
potentials (spikes) based on changes in field potential (47).
MEA recordings were performed over a 30-day period starting
at day 37 of neuronal differentiation. Representative raster
plots depicting neuronal firings (spikes) over a 250-second
period of continuous recording on days 5, 20, and 30 are
shown in Figure 5C. Spontaneous action potentials (APs) were
detected for all groups, confirming successful derivation of
functional neurons from all 3 genotypes. However, analysis of
spike frequencies revealed profound deficits in the mean and
maximum spike frequencies for FMR1KO1 and FXS neurons
compared with control neurons (Figure 5D–F), suggesting
altered neuronal network connectivity. To exclude the possi-
bility that the deficits in spike frequencies reflect preferential
loss of FMRP-deficient neurons, viability of neurons was
examined on day 20 of MEA recordings. We observed no dif-
ferences in neuronal numbers between the lines (Figure S5E),
indicating that the reduced MEA activity is not due to
reduced viability of FMRP-deficient neurons. Because dif-
ferences in MEA activity can also reflect intrinsic neuronal
differences, we analyzed the basic properties of AP firing in
FMRP-deficient and control neurons using patch clamp re-
cordings (Figure 5G and Table S9 in Supplement 1). While
there were no differences in the proportion of neurons with anetwork connectivity. (A) Representative images of neurite phenotype seg-
in pink/purple. (B) Neurite outgrowth and branching measurements. Values
twork activity using MEA recordings. n = 6 per genotype. (C) Raster plots of
A recordings. (D) Mean firing (spike) frequency. (E) Maximum firing (spike)
01 compared with control was determined by two-way ANOVA with Tukey’s
patch clamp. ANOVA, analysis of variance; FMR1KO, FMR1 knockout; FXS,
.
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FXS and 49 of 67 for FMR1KO1, p . .05, c2 test), the pro-
portion of such neurons was significantly larger when
compared with control neurons (45 of 79 for control, p ,
.001 vs. FXS, p , .05 vs. FMR1KO1, c2 test). These results
suggest that differences in the intrinsic properties of FMRP-
deficient neurons may also contribute to the deficits in MEA
activity observed.
Validation of FMRP Deficiency–Related Phenotypes
in FXS hiPSC Lines
To further validate the phenotypes observed in the isogenic
FMRP-deficient hESCs, we evaluated a subset of measures
using 2 independent FXS patient–derived and 2 control hiPSC
lines (25). We first confirmed that FMRP is indeed absent in
the FXS hiPSC lines by immunoblotting (Figure S9A in
Supplement 1). We analyzed transcriptional changes in neu-
rons differentiated from these hiPSC lines, collected on day
37, by RNA-seq. Principal component analysis of the tran-
scriptional profiles showed clustering of biological replicates
per line (Figure S9B). We identified 1061 upregulated and 1865
downregulated DEGs in hiPSC-derived FXS versus control
neurons, as depicted in the volcano plot (Figure S9C in
Supplement 1 and Table S10 in Supplement 2). Among the
DEGs, 373 genes were shared with the hESC-derived FXS and
isogenic FMR1KO transcriptome datasets, of which 122 were
upregulated and 251 were downregulated (Figure S9D and
Table S11 in Supplement 1). This overlap in DEGs among the
hESC-derived FXS and FMR1KO neurons and the hiPSC-derived
FXS neurons was highly significant (p = 2.6 3 102111, Fisher’s
exact test). Functional annotation of DEGs shared among
FMR1KO, FXS hESC–derived neurons, and FXS hiPSC–derived
neurons using pathway analysis showed enrichment of terms
related to kinase activity, amino acid transport, and RNA methyl-
ation for upregulated genes and showed enrichment of terms
related to axon guidance, neuron differentiation, transsynaptic
signaling, and messenger RNA splicing for downregulated genes
(Figure S9E in Supplement 1 and Table S12 in Supplement 2),
terms that are similar to those for the hESC-derived FXS and
isogenic FMR1KO neurons (Figure 2H).
To examine the FMRP deficiency–linked neurogenesis ab-
normalities, we performed the NR formation assay. Similar to
the FMR1KO lines, we found that FXS hiPSC–derived NR lu-
mens were significantly smaller compared with control cells
(Figure S9F, G in Supplement 1). In addition, we evaluated
cellular proliferation and observed a significantly increased
percentage of Ki671 and BrdU1 NPCs derived from the FXS
hiPSC lines compared with control cells, in line with the
increased NPC proliferation observed in the FMR1KO lines
(Figure S9H, I in Supplement 1). Furthermore, neurite
outgrowth was significantly reduced in FXS hiPSC neurons
over time compared with control neurons (Figure S9J in
Supplement 1). Together, these data demonstrate that key
neural phenotypes observed in the isogenic FMR1KO hESCs
are validated in FXS hESC and hiPSC lines.
DISCUSSION
Isogenic models represent well-controlled systems in which
molecular abnormalities can be readily attributed to the genetic10 Biological Psychiatry - -, 2020; -:-–- www.sobp.org/journallesion under study (48). Here, we developed an isogenic model
of FXS and identified transcriptional and proteomic changes in
several biological pathways important for brain development
and function in FMRP-deficient neurons. We also performed
functional validation showing several phenotypic deficits,
including abnormal NRs, increased NPC proliferation, reduced
neurite outgrowth, and impaired neuronal electrophysiological
activity. Finally, we performed RNA-seq and validated a subset
of the identified FXS phenotypes in FXS hiPSC–derived neural
cells. Our findings reveal key molecular signatures and neu-
rodevelopmental abnormalities arising from loss of FMRP.
A neurodevelopmental feature important for neuronal con-
nectivity is the branching and extension of neurites that
develop into axons and dendrites, which precede the forma-
tion of synaptic connections (17). With one exception (49), our
observation of profound neurite outgrowth deficits in FMR1KO
and FXS neurons supports previous reports in FMRP-deficient
mouse primary neurons (50,51) and hPSC-derived neurons
(13–15). The mechanisms underlying abnormal neurite growth
have not been investigated to date but are likely to involve
dysregulation of developmental pathways related to axonal
growth, which is reflected in downregulated genes in our
transcriptome and proteome datasets. It should be acknowl-
edged that differences in neurite outgrowth may also reflect
differences in differentiation protocols and neuronal types
analyzed.
One potential consequence of neurite growth deficits is
reduced neuronal network connectivity, which is reflected in
our MEA data showing reduced firing activity in FMRP-
deficient neurons. Previous patch clamp recordings of neu-
rons derived from FXS hESCs have also shown impaired ability
to fire repetitive action potentials and had reduced inward/
outward currents (17), consistent with our patch clamp
experiment showing reduced firing of multiple action potentials
in FMRP-deficient neurons. Furthermore, FMRP is a key
regulator in synaptic function and neurotransmission (52),
which is reflected in our datasets showing dysregulation of
genes involved in neuronal excitability, neurotransmitter
secretion, and synaptic transmission such as potassium
channels in FMRP-deficient neurons. Thus, the reduced
spontaneous firings observed in FXS and FMR1KO neurons
are likely the consequence of both impaired neuronal con-
nectivity and altered intrinsic firing properties.
It should be noted that hyperexcitability has also been re-
ported in FXS hPSC–derived neurons (21). Distinct excitability
phenotypes that can be observed in different hPSC-derived
neurons are consistent with variability in hyperexcitability
phenotypes between brain regions and neuronal subtypes
observed in rodent models of FXS (11,53–58). Indeed, this is
not surprising given that many of the voltage-dependent and
voltage-independent ion channels that regulate these pro-
cesses have distinct expression patterns across brain regions
and neuronal cell types. In the same way, the nature of the
excitability phenotype of hPSC-derived FMRP-deficient neu-
rons may vary depending on the specific differentiation pro-
tocol used and neuronal cell types analyzed.
The cellular and neuronal processes dysregulated in FMRP-
deficient neurons include neurogenesis, neuronal differentia-
tion, cell cycle progression, and neurotransmission. We were
able to corroborate a number of these changes functionally.
Neurodevelopmental Deficits in Human FXS Neurons
Biological
PsychiatryFirst, we discovered that the formation of NRs is abnormal in
the absence of FMRP. NRs are self-assembling structures
considered as surrogates of early neurulation and neural tube
formation (59,60). Second, a number of cell cycle genes and
proteins were found to be dysregulated in FXS and FMR1KO
neurons in our transcriptome and proteome analyses. These
include DNA replication initiators and regulators of cell cycle
checkpoints, among others. Cell cycle analysis, using neural
progenitor proliferation as an assay, showed increased prolif-
eration of FXS and FMR1KO neural progenitors compared with
control cells. In agreement with these results, studies using
murine and fly models of FXS have shown that FMRP functions
in the regulation of timing and proliferative capacities of neural
progenitors, with loss of FMRP leading to increased neural
progenitor proliferation (50,61,62). These findings suggest
altered cell cycle dynamics in FXS.
Our transcriptome and proteome analyses delineate dys-
regulated pathways affected in the absence of FMRP, high-
lighting mechanisms of potential relevance to FXS. Overall, we
presented an isogenic hPSC-based model that can serve as a
platform to investigate the pathophysiology of FXS and to
screen and validate targets of therapeutic potential in human
neurons.
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